Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans

Wall Street is optimistic about Geron Corporation (NASDAQ:GERN) as it plans to enhance Rytelo's commercialization. At the Stifel 2025 Healthcare Conference, Geron reiterated its strategy to address challenges and shift Rytelo's use to earlier treatment lines, aiming to boost sales. This positions Geron as a promising penny stock.

Geron | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 47.23 M

Geron Corporation’s Q3 2025 Financial Performance and Strategic Progress

Geron Corporation reported strong Q3 2025 financial results, with net product revenue from RYTELO reaching $47.2 million, despite a slight decline in demand. The company completed patient enrollment for its Phase 3 IMpactMF trial and improved its leadership team. Key metrics showed a reduced net loss and total revenues increased from $28.3 million to $47.2 million. Operating expenses rose slightly due to R&D and marketing investments. Geron remains optimistic about its strategic initiatives and plans to expand RYTELO’s market presence and advance its clinical pipeline.

Geron Corporation’s Earnings Call: Mixed Sentiments and Future Prospects

Geron Corporation's recent earnings call revealed mixed sentiments among stakeholders. Positive developments included a 15% increase in prescribing accounts and improved new patient starts, rising to 36%. However, the company faced challenges with a 3% decline in RYTELO demand and difficulties in positioning it as a second-line therapy. Geron maintains a strong financial position with $420 million in cash and has adjusted its operating expense guidance for 2025 to between $250 million and $260 million. Looking ahead, the company is optimistic about revenue growth in 2026, focusing on expanding RYTELO's market presence.

Strategic Initiatives and Market Expansion Drive Buy Rating for Geron

Tara Bancroft from TD Cowen has maintained a Buy rating on Geron with a price target of $4.00. This rating is supported by strategic initiatives aimed at enhancing market penetration for Rytelo, despite flat sales in Q3. Geron is focusing on increasing awareness among physicians and expanding its reach to earlier-line patients, which could boost revenue. Positive indicators include new ordering accounts and a high re-order rate, although increasing prescription depth remains a priority for sustainable growth.